ROCKLATAN Drug Patent Profile

When do Rocklatan patents expire, and when can generic versions of Rocklatan launch?

Rocklatan is a drug marketed by Alcon Labs Inc and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. One supplier is listed for this compound. Additional details are available on the latanoprost; netarsudil dimesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rocklatan

Rocklatan was eligible for patent challenges on December 18, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ROCKLATAN

US Patents:	17
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ROCKLATAN

Paragraph IV (Patent) Challenges for ROCKLATAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ROCKLATAN	Ophthalmic Solution	latanoprost; netarsudil dimesylate	0.005%/0.02%	208259	2	2021-12-20

US Patents and Regulatory Information for ROCKLATAN

ROCKLATAN is protected by seventeen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y	Y

International Patents for ROCKLATAN

When does loss-of-exclusivity occur for ROCKLATAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Finland

Hungary

Japan

Netherlands

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ROCKLATAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010241996
Australia	2010242800
Australia	2016201754

Supplementary Protection Certificates for ROCKLATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3053913	SPC/GB20/019	United Kingdom		PRODUCT NAME: NETARSUDIL; REGISTERED: UK EU/1/19/1400(NI) 20191121; UK PLGB 16058/003 20191121
3461484	C202130024	Spain		PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107
3053913	132020000000043	Italy		PRODUCT NAME: NETARSUDIL(RHOKIINSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1400, 20191121

ROCKLATAN (Netarsudil/Latanoprost) Investment Scenario and Patent/Exclusivity Fundamentals (US and Key Markets)

Last updated: July 22, 2026

Executive summary: ROCKLATAN is an ophthalmic fixed-dose combination (netarsudil 0.02% + latanoprost 0.005%) for primary open-angle glaucoma (POAG) and ocular hypertension. US exclusivity and patent posture drive the timing of generic substitution risk more than volume growth, because the dominant commercial tailwind is sustained prescription demand supported by payer adoption and physician switching. The investment case depends on (1) whether netarsudil/latanoprost fixed-dose combination exclusivity remains intact through the next generic entry window, (2) the defensibility of the specific formulation, combination, and method-of-use claims in the US, and (3) margin and channel share as competitors introduce alternative prostaglandin strategies and Rho-kinase class products.

What is ROCKLATAN (netarsudil/latanoprost) and why does it matter for investors?

ROCKLATAN is a glaucoma product that combines:

• Latanoprost (prostaglandin analog) for aqueous humor outflow enhancement.
• Netarsudil (Rho kinase inhibitor) for reducing resistance to aqueous outflow and improving trabecular outflow.

Clinical value proposition that affects revenue durability

• Fixed-dose convenience versus separate components lowers regimen burden and supports persistence.
• Mechanistic complementarity supports use in patients inadequately controlled on prostaglandin monotherapy.

Where investment risk concentrates

• Competitive substitution risk (other fixed combinations and Rho-kinase options).
• Patent and regulatory exclusivity through potential abbreviated approval pathways.
• Prescription retention and payer contract dynamics as generics and authorized low-cost alternatives emerge.

What patents protect ROCKLATAN netarsudil/latanoprost in the US?

ROCKLATAN’s defensibility typically rests on three patent buckets:

1. Fixed-dose combination compositions (netarsudil + latanoprost in a defined concentration range, pH, stabilizers, excipients).
2. Formulation and stability claims (specific vehicle, buffering system, antimicrobial system, viscosity or tonicity targets).
3. Method-of-use claims for treating POAG/ocular hypertension by administering the combination.

Investment relevance: In most ophthalmic fixed-dose products, generic risk is governed less by clinical differentiation and more by whether challengers can design around claim scope by altering excipients, concentration ranges, dosing regimens, or prodrug/formulation features.

Which claim categories drive Orange Book strength for ROCKLATAN?

Key evaluation dimensions used in investor patent models:

• Composition-of-matter vs. method-of-use split: composition claims tend to be harder to design around; method-of-use can be easier to avoid but still blocks labeling.
• Remaining term by jurisdiction: US filings typically set the latest generic window because US launch timing is tied to FDA exclusivity and patent expiration.
• Secondary patents: formulation patents often extend market exclusivity beyond initial composition filings, but enforceability depends on prosecution history and claim construction.

When does ROCKLATAN lose exclusivity in the US?

Generic entry timing in the US generally follows one of these sequences:

• Patent expiration for relevant Orange Book-listed patents.
• End of regulatory exclusivities (if any) that block FDA approval.
• If Paragraph IV is filed: litigation-driven stay mechanisms can delay approval even before ultimate patent expiry.

Investment relevance: For ophthalmics, fixed-dose combination products often face “claim-by-claim” erosion as generic applicants narrow to the formulation design-around and carve out method-of-use claims, making the exact remaining term by patent family critical.

What is the Orange Book status of ROCKLATAN?

The Orange Book status determines:

• Whether netarsudil/latanoprost is protected by one dominant composition patent or a layered estate.
• Whether there are multiple active patents with staggered expirations that can still block approval even after one patent falls.

Commercial linkage: A layered Orange Book listing increases the probability of delayed generic substitution and sustains pricing power, which is decisive for margin and free cash flow durability.

Are there Paragraph IV challenges against ROCKLATAN?

For fixed-dose ophthalmics, Paragraph IV activity can reduce valuation through:

• Triggering potential 180-day exclusivity for first filers.
• Accelerating settlement expectations.
• Narrowing product premium if generic versions reach pharmacies quickly after litigation timelines.

Investment relevance: The key is not only whether a Paragraph IV has been filed, but whether it targets:

• The most recent, last-expiring Orange Book patent.
• Claims that are strong to enforce (composition/formulation) versus weaker method-of-use claims.

What patent litigation affects ROCKLATAN generic entry risk?

Patent litigation determines:

• Whether the brand can secure a stipulated injunction or favorable settlement.
• Whether the parties agree to a design-around that can narrow future infringement theories.
• Whether multiple defendants exist, which can weaken leverage.

Investor lens: In ophthalmics, litigation outcomes can shift value through either (1) earlier-than-expected settlements allowing “at-risk” launches, or (2) delayed approvals via ongoing litigation stays.

How strong is the patent estate for ROCKLATAN netarsudil/latanoprost?

Patent strength is assessed through:

• Number of active claims families listed in the Orange Book.
• Remaining term of the last-to-expire patent family covering combination composition and formulation.
• Claim breadth indicators: concentration ranges, vehicle definitions, and dosing regimens.
• Enforcement history (if the family has been litigated previously).

Investment relevance: A strong estate yields sustained pricing power and reduces adverse scenario probability in generic launch models.

What formulations are protected by ROCKLATAN patents?

Formulation coverage matters because generic challengers often attempt to:

• Modify buffer systems, antimicrobial systems, or tonicity agents.
• Adjust pH within permitted ranges without entering claimed ranges.
• Use alternative excipients that maintain stability and comfort.

Investor lens: If the Orange Book estate contains narrow formulation claim language, a challenger may more easily design around. If claims are broad and cover functional properties (with concentration ranges and vehicle constraints), design-around becomes harder.

How does ROCKLATAN compare with other glaucoma fixed-dose and Rho-kinase products for competitive risk?

Competitive threats typically come from:

• Alternative prostaglandin combinations (different fixed-dose pairs with better adherence or payer positioning).
• Other Rho-kinase or NO-pathway agents that may shift market share in add-on therapy.
• Titration behavior: if physicians switch patients back to monotherapy due to tolerability, fixed-dose combination revenue can erode.

Investment relevance: The most important competitive variable is not “clinical superiority,” it is coverage and switching friction. If ROCKLATAN remains preferred on formularies, it can sustain demand even under competitive pressure.

What is the biosimilar risk for ROCKLATAN?

ROCKLATAN is a small molecule ophthalmic product, not a biologic. Biosimilar pathways do not apply.
Investment relevance: Generic substitution is the primary pathway for competitive erosion, not biosimilar entry.

What generic entry risks exist for ROCKLATAN?

Generic risk for a fixed-dose glaucoma product depends on:

• Whether challengers can meet formulation and labeling requirements without infringing composition/formulation claims.
• Whether method-of-use claims limit labeling for generic products.
• Whether an “authorized generic” or settlement design-around accelerates pharmacy substitution.

Investor lens: Evaluate the scenario split:

1. Full generic substitution at expiration with no litigation overhang.
2. Label carve-out that reduces interchangeable use.
3. Settlement with delayed entry or constrained formulation.

What manufacturing or IP barriers can delay generic launch for ROCKLATAN?

Manufacturing barriers that influence timeline:

• Stability and shelf-life of the combined vehicle.
• Replicating eye-drop comfort parameters relevant to tolerability and adherence.
• Validation of the combination’s physicochemical properties.

IP barriers that influence design-around success:

• Formulation patents that tightly control excipients and pH or specify antimicrobial composition.
• Concentration ratio and dosing regimen claims.

Investment scenario modeling: base case, downside, upside

Base case

• Continued demand with manageable competitive encroachment.
• Patent estate remains enforceable through the main generic window.
• Profitability holds via prescription retention and payer support.

Downside

• Early loss of key Orange Book coverage or unfavorable litigation reduces exclusivity sooner than modeled.
• First generic or authorized low-cost entrants gain meaningful share quickly due to cost advantage.
• Payer contracts reprice ROCKLATAN downward as generic availability increases.

Upside

• Litigation supports late settlement or stronger injunction posture.
• Brand retains preferred formulary position and expands patient share via adherence outcomes and physician behavior.
• Competitors fail to convert patients on tolerability grounds or payer restrictions.

Key commercial fundamentals investors track for ROCKLATAN

Even without patent events, ophthalmic growth and durability are driven by:

• Prescription volume trend (new starts and refill persistence).
• Net price realization (rebates, wholesaler and payer mix, channel competition).
• Share vs. competitor classes (especially prostaglandin-focused strategies and Rho-kinase alternatives).
• Safety/tolerability profile influencing adherence and persistence.

Investment implication: For fixed-dose combinations, persistence is a major driver of lifetime value; a brand can defend revenue longer through adherence than through brand advertising.

What regulatory milestones and FDA pathway dynamics matter for ROCKLATAN?

For generic entry risk, the most relevant regulatory dynamics are:

• Whether ANDA filings cite Paragraph IV and which Orange Book patents they challenge.
• Whether any pediatric exclusivity, orphan exclusivity, or other regulatory exclusivities apply (if present, they can delay approval regardless of some patent expirations).

Investment relevance: Regulatory timing determines when marketing authorization can become effective even if manufacturing is ready, so it affects launch-year revenue and discounting assumptions.

How do licensing deals or settlements affect ROCKLATAN valuation?

Settlements influence valuation via:

• Potential delayed entry terms for generic applicants.
• Scope-limited labeling if the settlement addresses method-of-use claims or design-around.
• Authorized generic arrangements that can partially protect revenue while still reducing margins.

Investment lens: Model settlements as two separate risks:

1. Launch timing risk (earlier entry lowers peak-to-trough returns).
2. Price erosion risk (even late entry can cause substantial price drops if authorized generics or multiple entrants arrive).

Geographic exclusivity: where is ROCKLATAN most exposed?

The highest-risk geographies are typically those with:

• Less favorable patent coverage or shorter effective term.
• Faster ANDA timelines and weaker enforceability for formulation claims.

Investment lens: For cross-market investors, the question is where exclusivity lapses first relative to planned R&D and market expansion.

Key Takeaways

• ROCKLATAN’s investment case is dominated by US Orange Book patent coverage, with generic substitution timing tied to the latest-to-expire combination/formulation protections and any Paragraph IV + litigation overhang.
• The biggest downside trigger is an adverse litigation or settlement path that enables earlier generic/authorized generic launch and forces payer repricing.
• Competitive risk is real but generally secondary to exclusivity duration and entry mechanics in fixed-dose ophthalmics.
• Upside scenarios come from continued payer preference and persistence plus litigation outcomes that preserve the primary revenue window.

FAQs

1. What triggers the fastest pricing erosion for fixed-dose ophthalmic combinations like ROCKLATAN?
2. How do design-around formulation changes (pH, buffers, excipients) typically affect infringement risk in ophthalmic ANDAs?
3. What is the most decision-relevant Orange Book patent category for delaying generic entry: composition, formulation, or method-of-use?
4. How do settlement terms between brand and Paragraph IV challengers usually shift launch timing for ophthalmic products?
5. What commercial metrics best predict whether ROCKLATAN retains share after new competitive entrants?

References

1. FDA Orange Book (Drugs@FDA database). U.S. Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA ANDA and Paragraph IV framework: 21 U.S.C. §355(j) and related regulations. U.S. Food and Drug Administration.